Predicting the Risk of Failure in Patients Undergoing Radiation Therapy for Localized Prostate Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00769223|
Recruitment Status : Recruiting
First Posted : October 9, 2008
Last Update Posted : October 15, 2014
RATIONALE: Gathering information about the Gleason score, prostate-specific antigen (PSA) level, and cancer stage from patients who have undergone radiation therapy for prostate cancer may help doctors predict how patients respond to treatment and help plan the best treatment.
PURPOSE: This clinical trial is studying the Gleason score, PSA level, and cancer stage in predicting outcome in patients who have undergone radiation therapy for localized prostate cancer.
|Condition or disease||Intervention/treatment|
|Prostate Cancer Radiation Toxicity||Other: medical chart review Other: questionnaire administration Procedure: quality-of-life assessment Radiation: brachytherapy Radiation: radiation therapy|
- Evaluate the value of the pre-operative Gleason score, prostate-specific antigen level, and clinical stage in predicting the risk of failure and death in patients who have undergone radiotherapy for localized prostate cancer.
OUTLINE: This is a multicenter study.
Patient medical records are reviewed to collect data about pre-treatment prostate biopsy, assigned Gleason score, prostate-specific antigen level, and radionucleotide bone scan.
Patients complete a Bowel Toxicity questionnaire to assess quality of life related to acute and long-term bowel toxicity after radiotherapy.
|Study Type :||Observational|
|Estimated Enrollment :||3500 participants|
|Official Title:||Pre-Operative Gleason Score and PSA and Clinical Stage in Predicting the Risk of Failure in Patients Undergoing Radiation Therapy for Localized Prostate Cancer|
|Study Start Date :||February 1993|
|Estimated Primary Completion Date :||December 2020|
|Estimated Study Completion Date :||June 2021|
- Value of the pre-operative Gleason score, prostate-specific antigen level, and clinical stage in predicting the risk of failure and death [ Time Frame: December 2020 ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00769223
|United States, California|
|UCSF Helen Diller Family Comprehensive Cancer Center||Recruiting|
|San Francisco, California, United States, 94115|
|Contact: Clinical Trials Office - UCSF Helen Diller Family Comprehensi 877-827-3222|
|Principal Investigator:||Mack Roach, MD||University of California, San Francisco|